SQZ BIOTECHNOLOGIES COMPANY Research and Development Expense
SQZ BIOTECHNOLOGIES COMPANY reported Research and Development Expense of $10.50 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2023-11-08
- SQZ BIOTECHNOLOGIES COMPANY research and development expense for the quarter ending 2023-09-30 was $10.50M, a 46.49% decline year-over-year.
- SQZ BIOTECHNOLOGIES COMPANY research and development expense for the quarter ending 2023-06-30 was $12.73M, a 32.15% decline year-over-year.
- SQZ BIOTECHNOLOGIES COMPANY research and development expense for the quarter ending 2023-03-31 was $12.98M, a 23.72% decline year-over-year.
- SQZ BIOTECHNOLOGIES COMPANY research and development expense for the quarter ending 2022-12-31 was $15.58M, a 9.43% decline year-over-year.
- SQZ BIOTECHNOLOGIES COMPANY research and development expense for fiscal 2022 was $70.98M, a 1.19% increase from fiscal 2021.
- SQZ BIOTECHNOLOGIES COMPANY research and development expense for fiscal 2021 was $70.15M, a 36.09% increase from fiscal 2020.
- SQZ BIOTECHNOLOGIES COMPANY research and development expense for fiscal 2020 was $51.55M, a 42.78% increase from fiscal 2019.
- SQZ BIOTECHNOLOGIES COMPANY research and development expense for fiscal 2019 was $36.10M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2023-09-30 | $10.50M 10-Q · filed 2023-11-08 | $23.23M derived: sum of 2 quarters · filed 2023-11-08 | $36.21M 10-Q · filed 2023-11-08 | $51.79M derived: sum of 4 quarters · filed 2023-11-08 |
| 2023-06-30 | $12.73M 10-Q · filed 2023-08-10 | $25.70M 10-Q · filed 2023-08-10 | $41.29M derived: sum of 3 quarters · filed 2023-08-10 | $60.92M derived: sum of 4 quarters · filed 2023-11-08 |
| 2023-03-31 | $12.98M 10-Q · filed 2023-05-10 | $28.56M derived: sum of 2 quarters · filed 2023-05-10 | $48.19M derived: sum of 3 quarters · filed 2023-11-08 | $66.95M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-12-31 | $15.58M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $35.21M derived: sum of 2 quarters · filed 2023-11-08 | $53.97M derived: sum of 3 quarters · filed 2023-11-08 | $70.98M 10-K · filed 2023-03-22 |
| 2022-09-30 | $19.63M 10-Q · filed 2023-11-08 | $38.39M derived: sum of 2 quarters · filed 2023-11-08 | $55.40M 10-Q · filed 2023-11-08 | $72.61M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $18.76M 10-Q · filed 2023-08-10 | $35.77M 10-Q · filed 2023-08-10 | $52.98M derived: sum of 3 quarters · filed 2023-08-10 | $73.50M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $17.01M 10-Q · filed 2023-05-10 | $34.22M derived: sum of 2 quarters · filed 2023-05-10 | $54.74M derived: sum of 3 quarters · filed 2023-05-10 | $72.42M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $17.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $37.73M derived: sum of 2 quarters · filed 2023-03-22 | $55.41M derived: sum of 3 quarters · filed 2023-03-22 | $70.15M 10-K · filed 2023-03-22 |
| 2021-09-30 | $20.52M 10-Q · filed 2022-11-09 | $38.20M derived: sum of 2 quarters · filed 2022-11-09 | $52.94M 10-Q · filed 2022-11-09 | $66.67M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $17.68M 10-Q · filed 2022-08-04 | $32.42M 10-Q · filed 2022-08-04 | $46.15M derived: sum of 3 quarters · filed 2022-08-04 | $60.06M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $14.74M 10-Q · filed 2022-05-10 | $28.47M derived: sum of 2 quarters · filed 2022-05-10 | $42.38M derived: sum of 3 quarters · filed 2022-05-10 | $54.42M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $13.73M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | $27.64M derived: sum of 2 quarters · filed 2022-03-16 | $39.68M derived: sum of 3 quarters · filed 2022-03-16 | $51.55M 10-K · filed 2022-03-16 |
| 2020-09-30 | $13.91M 10-Q · filed 2021-11-10 | $25.95M derived: sum of 2 quarters · filed 2021-11-10 | $37.81M 10-Q · filed 2021-11-10 | $47.59M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $12.04M 10-Q · filed 2021-08-04 | $23.91M 10-Q · filed 2021-08-04 | $33.68M derived: sum of 3 quarters · filed 2021-08-04 | $42.17M derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-03-31 | $11.87M 10-Q · filed 2021-05-11 | $21.65M derived: sum of 2 quarters · filed 2021-05-11 | $30.14M derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | $9.78M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $18.27M derived: sum of 2 quarters · filed 2021-03-18 | $36.10M 10-K · filed 2021-03-18 | |
| 2019-09-30 | $8.49M 10-Q · filed 2020-12-10 | $26.32M 10-Q · filed 2020-12-10 |